VolitionRx Limited (VNRX) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

VolitionRx Limited

VNRX

AMEX

Unprofitable

49M

Medical - Diagnostics & Research

Next Earning date - 12 May 2025

49M

Medical - Diagnostics & Research

Next Earning date - 12 May 2025

0.49USD

-0.00 ( -0.61%)

Market Closed (as of Apr 25, 20:00 EDT)

Relative Strenght

Volume Buzz

-28%

Earning Acce

Yes

Dist 52w H.

49%

Overview Chart

Quote Panel

Updated April 27, 2025

1W 1.88 % 1M -11.45 % 3M -21.07 % 1Y -43.29 %

Key Metrics

Market Cap
49.08M
Shares Outstanding
100.78M
Share in Float
74.62M
Dividende
0

Earning Date
12 May 2025
Price Target
0.487
Average Volume
167280
Beta
1.162

Range
0.42-0.95
Industry
Medical - Diagnostics & Research
Website
https://www.volition.com
Sector
Healthcare

Quote Panel

Updated April 27, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

39.79x

P/S Ratio

-1.71x

P/B Ratio

-0.2

Debt/Equity

-2186.3%

Net Margin

$-0.3

EPS

How VNRX compares to sector?

P/E Ratio

Fundamentals

Relative Strength

VNRX

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

VNRX

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$7M

3803%

2025-Revenue

$0.13

-103%

2025-EPS

$7M

-38%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q1.23

N/A

-0.15
vs -0.14

Q2.23

N/A

-0.14
vs -0.14

Q3.23

N/A

-0.11
vs -0.14

Q4.23

N/A

-0.11
vs -0.13

Q1.24

N/A

-0.10
vs -0.15

Q2.24

N/A

-0.08
vs -0.14

Q3.24

N/A

-0.07
vs -0.11

Q4.24

N/A

-0.11
vs -0.11

Q1.25

N/A

-0.04
vs -0.10

Q2.25

N/A

-0.04
vs -0.08

Sales Growth

YoY

Current

Estimates

Q1.23

+31%

149.8K vs 114.2K

Q2.23

+444%

216.3K vs 39.8K

Q3.23

+405%

165.2K vs 32.7K

Q4.23

+104%

244K vs 119.7K

Q1.24

+15%

171.5K vs 149.8K

Q2.24

+83%

395.8K vs 216.3K

Q3.24

+187%

474.5K vs 165.2K

Q4.24

-21%

191.7K vs 244K

Q1.25

+435%

917.2K vs 171.5K

Q2.25

+159%

1M vs 395.8K

Return on Equity

QoQ

Q1.23

+376%

3.76
vs 2.81

Q2.23

-162%

-1.62
vs 3.76

Q3.23

+410%

4.1
vs -1.62

Q4.23

+111%

1.11
vs 4.1

Q1.24

+54%

0.54
vs 1.11

Q2.24

+32%

0.32
vs 0.54

Q3.24

+27%

0.27
vs 0.32

Q4.24

+23%

0.23
vs 0.27

Institutionnal Ownership

QoQ

Q1.23

43
vs 39

10%

Q2.23

38
vs 43

-12%

Q3.23

31
vs 38

-18%

Q4.23

29
vs 31

-6%

Q1.24

24
vs 29

-17%

Q2.24

29
vs 24

21%

Q3.24

24
vs 29

-17%

Q4.24

28
vs 24

17%

Earnings Growth

Latest News

seekingalpha.com

less than 1 hour ago

VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript

prnewswire.com

8 hours ago

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

prnewswire.com

8 hours ago

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

prnewswire.com

8 hours ago

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

prnewswire.com

9 hours ago

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

prnewswire.com

16 hours ago

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Company Description

0.49USD

N/A

39.79x

-1.71x

-0.2

-2186.3%

$-0.3

$7M

$0.13

$7M

Earnings Growth

Latest News

Latest News

Latest News

$7M

$0.13

$7M

Company Description

0.49USD

N/A

39.79x

-1.71x

-0.2

-2186.3%

$-0.3